American Capital Management Inc buys $38,721,294 stake in ResMed (RMD)

ResMed (RMD) : American Capital Management Inc scooped up 83,085 additional shares in ResMed during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 25, 2016. The investment management firm now holds a total of 693,930 shares of ResMed which is valued at $38,721,294.ResMed makes up approximately 3.51% of American Capital Management Inc’s portfolio.

ResMed opened for trading at $55.85 and hit $56.26 on the upside on Monday, eventually ending the session at $56.13, with a gain of 0.59% or 0.33 points. The heightened volatility saw the trading volume jump to 7,24,908 shares. Company has a market cap of $7,881 M.

Other Hedge Funds, Including , Duncker Streett Co Inc reduced its stake in RMD by selling 3,511 shares or 80.14% in the most recent quarter. The Hedge Fund company now holds 870 shares of RMD which is valued at $48,546. ResMed makes up approx 0.02% of Duncker Streett Co Inc’s portfolio.Cornerstone Advisors boosted its stake in RMD in the latest quarter, The investment management firm added 8 additional shares and now holds a total of 39 shares of ResMed which is valued at $2,368.Btim Corp. boosted its stake in RMD in the latest quarter, The investment management firm added 34,614 additional shares and now holds a total of 103,686 shares of ResMed which is valued at $6,295,814. ResMed makes up approx 0.11% of Btim Corp.’s portfolio. Palo Capital sold out all of its stake in RMD during the most recent quarter. The investment firm sold 15,090 shares of RMD which is valued $916,265.Acadian Asset Management boosted its stake in RMD in the latest quarter, The investment management firm added 237,405 additional shares and now holds a total of 265,952 shares of ResMed which is valued at $15,890,632. ResMed makes up approx 0.08% of Acadian Asset Management’s portfolio.

On the company’s financial health, ResMed reported $0.68 EPS for the quarter, missing the analyst consensus estimate by $ -0.01 based on the information available during the earnings call on Apr 26, 2016. Analyst had a consensus of $0.69. The company had revenue of $453.88 million for the quarter, compared to analysts expectations of $455.94 million. The company’s revenue was up 7.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.65 EPS.

Many Wall Street Analysts have commented on ResMed. ResMed was Upgraded by Macquarie to ” Neutral” on Apr 28, 2016. ResMed was Downgraded by Piper Jaffray to ” Neutral” on Apr 27, 2016. Barclays Resumed ResMed on Apr 7, 2016 to “Underweight”, Price Target of the shares are set at $55.

ResMed Inc. is engaged in the development manufacturing distribution and marketing of medical products for the diagnosis treatment and management of respiratory disorders with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders including airflow generators diagnostic products mask systems headgear and other accessories. It produces continuous positive airway pressure variable positive airway pressure and AutoSet systems for the titration and treatment of SDB. Its products also include S9 Escape AirSense 10 Elite AirSense 10 CPAP S9 VPAP S S9 VPAP ST S9 VPAP Adapt S9 VPAP ST-A S9 VPAP COPD and AirCurve 10 V Auto among others. It markets sleep recorders for the diagnosis and titration of SDB in sleep clinics and hospitals. Its products include Quattro FX Swift FX for Her Mirage FX for Her Pixi Pediatric Mask Quattro FX for Her Swift FX Bella Swift FX Nano AirFit N10 and Apnealink Air.

Leave a Reply

ResMed - Is it time to Sell?

Top Brokerage Firms are advising their investors on ResMed. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.